Levels of CXCL9, CXCL10, and CXCL11 Reflect Pulmonary and Multi-Organ Severity in GRADS

Background Sarcoidosis is a granulomatous disease with heterogeneous clinical manifestations and limited reliable biomarkers to support disease assessment and management. The IFN-γ–inducible chemokines, CXCL9, CXCL10, and CXCL11, are involved in sarcoidosis pathophysiology and have been associated with pulmonary abnormalities and multi-organ involvement. This study aimed to replicate these associations in a large, multicenter sarcoidosis cohort. Methods Chemokine levels were measured by ELISA in serum samples from the Genomic Research in Alpha-1 Antitrypsin Deficiency and Sarcoidosis (GRADS) cohort (n=353). Cross-sectional associations with percent predicted FVC, FEV1, DLCO, chest radiographic Scadding stage, and number of involved organs were assessed with multivariable linear and Poisson regression modeling with adjustment for immunosuppression, enrollment site, relevant demographics, and smoking, where applicable. Additional analyses evaluated the same associations with 12 other clinical blood tests. Results Higher levels of all three chemokines were associated with lower percent predicted pulmonary function values, with CXCL11 showing the largest effect sizes (−9.9 to −11.6% per 10-fold increase). All three chemokines were also associated with higher Scadding stage, again largest for CXCL11 (31.4% increase per category), and greater organ number, largest for CXCL11 (59% increase per 10-fold increase). In contrast, none of the other blood tests demonstrated consistent associations across all clinical features. Conclusions These results replicate and extend prior observations that CXCL9, CXCL10, and CXCL11 are associated with the degree of pulmonary impairment, radiographic extent, and total organ involvement in sarcoidosis. Prospective studies are needed to define their role in longitudinal monitoring and clinical decision-making.

Authors

Institutions

Publication Details

Journal
ERJ Open Research
Published
2026-11-12
DOI
https://doi.org/10.1183/23120541.01197-2026
Primary Topic
Sarcoidosis and Beryllium Toxicity Research
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Levels of CXCL9, CXCL10, and CXCL11 Reflect Pulmonary and Multi-Organ Severity in GRADS

N. Arger, Laura Koth, Elaine Isabel Allen
ERJ Open Research
Sarcoidosis and Beryllium Toxicity Research
article

Levels of CXCL9, CXCL10, and CXCL11 Reflect Pulmonary and Multi-Organ Severity in GRADS

N. Arger, Laura Koth, Elaine Isabel Allen
article en

Abstract

Background Sarcoidosis is a granulomatous disease with heterogeneous clinical manifestations and limited reliable biomarkers to support disease assessment and management. The IFN-γ–inducible chemokines, CXCL9, CXCL10, and CXCL11, are involved in sarcoidosis pathophysiology and have been associated with pulmonary abnormalities and multi-organ involvement. This study aimed to replicate these associations in a large, multicenter sarcoidosis cohort. Methods Chemokine levels were measured by ELISA in serum samples from the Genomic Research in Alpha-1 Antitrypsin Deficiency and Sarcoidosis (GRADS) cohort (n=353). Cross-sectional associations with percent predicted FVC, FEV1, DLCO, chest radiographic Scadding stage, and number of involved organs were assessed with multivariable linear and Poisson regression modeling with adjustment for immunosuppression, enrollment site, relevant demographics, and smoking, where applicable. Additional analyses evaluated the same associations with 12 other clinical blood tests. Results Higher levels of all three chemokines were associated with lower percent predicted pulmonary function values, with CXCL11 showing the largest effect sizes (−9.9 to −11.6% per 10-fold increase). All three chemokines were also associated with higher Scadding stage, again largest for CXCL11 (31.4% increase per category), and greater organ number, largest for CXCL11 (59% increase per 10-fold increase). In contrast, none of the other blood tests demonstrated consistent associations across all clinical features. Conclusions These results replicate and extend prior observations that CXCL9, CXCL10, and CXCL11 are associated with the degree of pulmonary impairment, radiographic extent, and total organ involvement in sarcoidosis. Prospective studies are needed to define their role in longitudinal monitoring and clinical decision-making.

ERJ Open Research
University of California, San Francisco (US)
CHEST Foundation, National Heart, Lung, and Blood Institute
Good health and well-being
Sarcoidosis and Beryllium Toxicity Research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon